Iridium Kankernetwerk

Immunohistochemistry for c-MET, HLA class II, and CD68 does not show prognostic value in early-stage classic Hodgkin lymphoma patients in the EORTC-GELA H9 intergroup randomised trial

Background In classic Hodgkin lymphoma (cHL), identifying high-risk patients is crucial for tailored treatment. Clinical risk factors are useful, but there is room for improvement. Although many diagnostic tissue-based biomarkers have been described to correlate with prognosis, n...

StereoBed - salvage stereotactic body radiotherapy of the prostate bed for biochemical recurrence after radical prostatectomy: study protocol for a randomized phase II/III trial

In cases of biochemical recurrence (BCR) after radical prostatectomy, salvage radiotherapy (RT) is a well-established standard-of-care treatment. Stereotactic body radiotherapy (SBRT) may offer a shorter treatment duration and favorable radiobiological characteristics, but eviden...